Skip to Content

Myalept Side Effects

Generic Name: metreleptin

Note: This page contains information about the side effects of metreleptin. Some of the dosage forms included on this document may not apply to the brand name Myalept.

In Summary

More frequent side effects include: proteinuria and urticaria. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to metreleptin: subcutaneous powder for solution, subcutaneous solution

In addition to its needed effects, some unwanted effects may be caused by metreleptin (the active ingredient contained in Myalept). In the event that any of these side effects do occur, they may require medical attention.

Major Side Effects

You should check with your doctor immediately if any of these side effects occur when taking metreleptin:

More common:
  • Anxiety
  • blurred vision
  • body aches or pain
  • burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
  • chills or fever
  • cold sweats
  • confusion
  • dizziness
  • fast heartbeat
  • headache
  • increased hunger
  • nausea
  • nervousness
  • shakiness
  • sore throat
  • unusual tiredness or weakness
Less common:
  • Bloating
  • pains in the stomach, side, or abdomen, possibly radiating to the back
  • vomiting

Minor Side Effects

Some of the side effects that can occur with metreleptin may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common:
  • Back pain
  • diarrhea
  • ear drainage
  • earache or pain in the ear
  • muscle pain or stiffness
  • pain in the joints
  • weight loss

For Healthcare Professionals

Applies to metreleptin: subcutaneous powder for injection

Metabolic

Very common (10% or more): Hypoglycemia (13%), decreased weight (13%)[Ref]

Nervous system

Very common (10% or more): Headache (13%)
Common (1% to 10%): Dizziness, paresthesia[Ref]

Gastrointestinal

It has been reported that two patients (4%) had symptoms of pancreatitis. Both had a medical history of pancreatitis.[Ref]

Very common (10% or more): Abdominal pain (10%)
Common (1% to 10%): Nausea, diarrhea, pancreatitis[Ref]

Genitourinary

Common (1% to 10%): Ovarian cyst

Hematologic

Common (1% to 10%): Anemia[Ref]

Hypersensitivity

Common (1% to 10%): Injection-site erythema, urticaria
Frequency not reported: Generalized rash[Ref]

Immunologic

In vitro neutralizing activity anti-metreleptin (the active ingredient contained in Myalept) antibodies were identified in 2 patients (n=33) with generalized lipodystrophy who showed severe infections and worsening metabolic control (increases in HbA1c and/or triglycerides). Three patients with anti-metreleptin antibodies without lipodystrophy showed excessive weight gain, and/or development of glucose intolerance or diabetes.

In clinical trials, anti-metreleptin antibodies were detected in 36 of 43 generalized lipodystrophy patients, with titers ranging from 1:5 to 1:1,953, 125; however, these numbers may be misleading as detection of antibody formation is highly dependent on the sensitivity and specificity of the assay (the assays utilized in clinical trials lacked sensitivity), handling of the sample, concomitant drugs, and underlying disease. Due to incompleteness of the immunogenicity data, the clinical significance and the magnitude and persistence of the anti-drug responses are not well characterized.[Ref]

Frequency not reported: Autoimmune disorder, immunogenicity[Ref]

Musculoskeletal

Common (1% to 10%): Arthralgia, back pain[Ref]

Other

Common (1% to 10%): Pyrexia, ear infection, fatigue[Ref]

Renal

Common (1% to 10%): Proteinuria[Ref]

Respiratory

Common (1% to 10%): Upper respiratory tract infection[Ref]

Oncologic

Frequency not reported: T-cell lymphoma, anaplastic large cell lymphoma

Three cases of T-cell lymphoma were reported among patients with acquired generalized lipodystrophy; 2 patients diagnosed with peripheral T-cell lymphoma during treatment had immunodeficiency and significant hematologic abnormalities including severe bone marrow abnormalities prior to starting treatment. Anaplastic large cell lymphoma was reported in 1 patient receiving this drug who did not have hematologic abnormalities before treatment.

References

1. "Product Information. Myalept (metreleptin)." Bristol-Myers Squibb, Princeton, NJ.

Not all side effects for Myalept may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide